Skip to main content
Martin Steinberg, MD, Hematology, Boston, MA

MartinHSteinbergMD

Hematology Boston, MA

Professor, Medicine, Boston University School of Medicine

Are you Dr. Steinberg?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 38 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    830 Harrison Ave
    Moakley, 3rd Floor
    Boston, MA 02118
    Phone+1 617-638-6428
    Fax+1 617-638-5756

Summary

  • Dr. Martin Steinberg, MD is a hematologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Boston Medical Center and is a Professor at Boston University School of Medicine.

Education & Training

  • Tufts Medical Center
    Tufts Medical CenterResidency, Internal Medicine, 1966 - 1968
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineInternship, Transitional Year, 1962 - 1963
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1962

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1965 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1979

Publications & Presentations

PubMed

Press Mentions

  • What if a CRISPR Cure Isn’t Such an Easy Choice?
    What if a CRISPR Cure Isn’t Such an Easy Choice?November 9th, 2023
  • FDA Approves Two Gene Therapies for Sickle Cell, Including First CRISPR-Based Medicine
    FDA Approves Two Gene Therapies for Sickle Cell, Including First CRISPR-Based MedicineDecember 12th, 2023
  • FDA Weighs Gene-Editing Treatments’ Curative Possibilities Against Potential Risks
    FDA Weighs Gene-Editing Treatments’ Curative Possibilities Against Potential RisksDecember 12th, 2023

Grant Support

  • Globin Gene Expression In Sickle Cell Genotype-Specific IPS CellsNational Heart, Lung, And Blood Institute2011
  • Sickle Cell ScholarNational Heart, Lung, And Blood Institute2008–2011
  • Administrative CoreNational Heart, Lung, And Blood Institute2008–2011
  • Boston Comprehensive Sickle Cell CenterNational Heart, Lung, And Blood Institute2003–2011
  • Genetic Diversity Of Sickle Cell AnemiaNational Heart, Lung, And Blood Institute2009–2010
  • Genome-Wide Association Studies In Sickle Cell Anemia And In CentenariansNational Heart, Lung, And Blood Institute2007–2010
  • Genetic Modulation Of Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2006–2010
  • Genetic Modulation Of Sickle Cell AnemiaFogarty International Center2006–2008
  • Pulse Arginine Butyrate In Sickle Cell DiseaseNational Center For Research Resources2007
  • Research Scholar ProgramNational Heart, Lung, And Blood Institute2004–2007
  • Core--Inter Center Collaborative Clinical ResearchNational Heart, Lung, And Blood Institute2004–2007
  • Core--Clinical CoreNational Heart, Lung, And Blood Institute2004–2007
  • Determinants Of Hbf Response To HydroxyureaNational Heart, Lung, And Blood Institute2002–2005
  • Genetic Modulation Of Sickle Cell AnemiaNational Heart, Lung, And Blood Institute2001–2005
  • Comprehensive Sickle Cell CenterNational Heart, Lung, And Blood Institute2001–2002